DevCurationThe Premier Voice of the Entire Tech Ecosystem
Home
Where the Money Moved
News
Events
Investor Spotlight
Company Spotlight
Frameworks
DevCuration
Home
Where the Money Moved
News
Events
Investor Spotlight
Company Spotlight
Frameworks
DevCuration
Latest
Valkryn Raises $15M Seed for Autonomous Defense TestingValkryn Raises $15M Seed for Autonomous Defense Testing|KKR Completes $5.7B Acquisition of Integer Holdings|Argonaut Private Equity Closes $606M Fund VI for Industrials|Compute Desk Raises $45M Seed for GPU Compute Markets|Ramon.Space Raises $124M to Scale Satellite Computing|Science Corporation Raises $400M to Expand PRIMA Access|Remanence Raises $30M Seed for Continual-Learning AI|Isomorphic Labs Raises $5B Series C for AI Drug Design|Traitomic Raises €20M for Customer Trait Development|Inverto Earth Secures Nearly $2.4M for Coastal Restoration|Valkryn Raises $15M Seed for Autonomous Defense TestingValkryn Raises $15M Seed for Autonomous Defense Testing|KKR Completes $5.7B Acquisition of Integer Holdings|Argonaut Private Equity Closes $606M Fund VI for Industrials|Compute Desk Raises $45M Seed for GPU Compute Markets|Ramon.Space Raises $124M to Scale Satellite Computing|Science Corporation Raises $400M to Expand PRIMA Access|Remanence Raises $30M Seed for Continual-Learning AI|Isomorphic Labs Raises $5B Series C for AI Drug Design|Traitomic Raises €20M for Customer Trait Development|Inverto Earth Secures Nearly $2.4M for Coastal Restoration
DevCuration

The premier voice of the tech ecosystem, from ideation to enterprise.

Explore

  • Where the Money Moved
  • Events
  • Articles & Analysis

Spotlights

  • Investor Spotlight
  • Company Spotlight
  • Frameworks

Company

  • About Us
  • Privacy Policy
  • Terms of Service
© 2026 DevCuration. All rights reserved.
TwitterLinkedIn
Logos provided by Logo.dev
Back to articles
November 18, 2026
•Jesse LandryJesse Landry

KKR Completes $5.7B Acquisition of Integer Holdings

Integer’s stock has stopped trading, but the medical-device companies depending on its manufacturing still need their next production run. The Plano, Texas supplier now has a new owner behind that work, following the completion of a transaction valued at approximately $5.7B in enterprise value.

Integer Holdings Corporation said on November 17, 2026, that an affiliate of investment funds managed by KKR had completed its acquisition. Shareholders receive $127 per share in cash, and Integer’s common stock will no longer be listed on the New York Stock Exchange. The purchase puts a global medical-device contract development and manufacturing organization, or CDMO, inside KKR’s portfolio.

For customers, the relevant question is how the new ownership supports the engineering and manufacturing they buy. For employees, KKR’s previously announced intention to introduce broad-based ownership adds a second set of interests to the transaction, with the program’s implementation and terms still to be explained.

What the acquisition changes for Integer

The transaction completes a process that began with Integer’s board-led strategic review, announced in April. Integer and KKR announced their agreement on August 3, and shareholders approved it on October 21. A September announcement disclosed early termination of the US antitrust waiting period; the November completion announcement establishes that the deal has moved beyond the earlier timetable for a year-end closing.

KKR committed to the investment through its core private equity strategy. The original agreement announcement described a combination of equity from KKR-managed funds and committed debt financing. That distinction matters when reading the headline: the approximately $5.7B enterprise value measures the transaction, rather than a disclosed budget of new money for Integer’s factories.

The original transaction announcement did not give a standalone budget for capacity expansion or technology spending. Customers assessing future commitments will therefore need specific project decisions from Integer rather than treating the purchase consideration as available operating capital.

The acquisition also changes who receives the financial benefit of future improvement. Public shareholders exit for cash, while the buyer takes ownership of a business whose value depends on serving device manufacturers over time. That makes the proposed employee program commercially relevant to the growth plan, even before any details about individual participation are available.

The manufacturing business behind the price

Integer serves cardio and vascular, cardiac rhythm management and neuromodulation markets through brands including Greatbatch Medical and Lake Region Medical. Its place in the industry is behind the companies bringing devices to market, supplying development and manufacturing capabilities that can remain largely invisible to the patient using the finished product. Owning that supplier gives KKR exposure to the work supporting multiple device categories.

The business carries a history of combining capabilities. Integer’s corporate history traces the technologies and predecessor businesses behind its present brands, while its 2016 proxy describes the acquisition of Lake Region Medical in 2015 as a substantial expansion of the company. The investment case therefore includes an established manufacturing organization with accumulated expertise and customer relationships, rather than a newly formed product company seeking its first commercial foothold.

A buyer evaluating this kind of supplier is also evaluating the organization around the equipment. The engineering relationship, manufacturing execution and quality work have to remain useful to customers as investment priorities develop under private ownership.

President and CEO Payman Khales brings experience from inside that operation. He previously served as COO and led Integer’s cardio and vascular business, with responsibility extending into manufacturing strategy. His current assignment connects the ambitions of a new financial owner with the engineering, quality and production work that customers already expect Integer to perform.

A growth plan meets uneven operating results

The financial picture entering the buyout gives that assignment some urgency. Integer’s third-quarter results, published October 29 for the period ended October 2, reported sales of $450M, down 3.9% from a year earlier. GAAP operating income from continuing operations fell 50% to $28M, while adjusted EBITDA, a non-GAAP measure, declined 17% to $88M.

Performance differed across the business. Cardio and vascular sales fell approximately 5% to $263M, while cardiac rhythm management and neuromodulation sales grew approximately 4% to $176M. Those results give the investment story more texture than a general promise of healthcare growth: management is working with categories moving at different speeds inside the same manufacturing group.

The numbers also discourage treating all of Integer’s end markets as one demand story. Decisions about investment and execution will have to reflect the mix of products and customers behind the consolidated results, with attention to where volumes are growing and where they are falling.

KKR Partner Max Lin, who leads the firm’s Americas private equity healthcare team, described opportunities to expand Integer’s capabilities in the closing announcement. The stated priorities include investing in people, capabilities and technologies. Reading those plans alongside the latest results suggests an operating agenda that must accommodate growth opportunities while improving performance in weaker areas, without assuming that ownership alone changes customer demand.

Employee ownership enters the production conversation

KKR said at signing that it intended to introduce a broad-based employee ownership and engagement program after the transaction closed. An employee FAQ filed with the SEC also described that intention and said more details would follow. The reviewed closing materials do not establish the program’s launch, allocations or eventual payouts, so employees are still waiting for the economics behind the proposal.

The idea has a direct connection to the asset KKR purchased. Medical-device manufacturing depends on people translating engineering requirements into repeatable production, and the ownership proposal would give those people a stake in the business’s future value. The specific incentive will depend on how the program is designed and communicated, particularly for employees whose daily work is far removed from a transaction announcement.

Healthcare capital can support very different stages of bringing a treatment or device to patients, as DevCuration’s coverage of Science Corporation’s PRIMA expansion and the proposed Ollin Biosciences acquisition illustrates. Integer’s transaction sits in the manufacturing relationships supporting that wider ecosystem. Khales and KKR now have a private ownership structure through which to make investment decisions, while the people carrying those decisions into production wait to learn how their own participation will work.

DevCuration Data

Healthcare funding, last 30 days

DevCuration's funding database tracked 13 Healthcare rounds totaling $195.8M in disclosed capital over the past 30 days. Recent deals we covered:

  • Skribe Medical Discloses $1.65M for Cardiac WearablesPre-Seed · $1.65M · Nov 13
  • iCareManager Gains Five Elms Growth Backing for IDD CareGrowth · Nov 12
  • Triplemoon Raises $4M Seed Extension for Pediatric CareSeed Extension · $4M · Nov 12
  • EnVision Endoscopy Raises $11.5M Series A for SimpleStitchSeries A · $11.5M · Nov 12
  • VisiQuate Acquires Artiva HCx for Revenue Cycle WorkflowsNov 8
All tracked rounds

Frequently Asked Questions

How does the $5.7B enterprise value relate to investment in Integer’s operations?

The approximately $5.7B figure is the acquisition’s enterprise value. KKR described financing the purchase with fund equity and committed debt, while separately outlining investment priorities in capacity, technology and people. No standalone new operating investment budget was disclosed in the reviewed transaction announcements.

Which medical-device markets depend on Integer’s capabilities?

Integer serves cardio and vascular, cardiac rhythm management and neuromodulation markets. Its Greatbatch Medical and Lake Region Medical brands provide engineering and manufacturing capabilities for medical-device companies.

What is known about the proposed employee ownership program?

KKR said it intended to introduce a broad-based ownership and engagement program after closing. The reviewed completion materials do not establish a launch date, individual allocations or payout terms.

What operating conditions did Integer report before the acquisition closed?

Integer reported Q3 2026 sales of $450M, down 3.9% year over year, and GAAP operating income from continuing operations of $28M, down 50%. Cardiac rhythm management and neuromodulation sales grew while cardio and vascular sales declined.

What changed for Integer’s public shareholders after completion?

The acquisition completed on November 17, 2026, with shareholders receiving $127 per share in cash. Integer’s common stock ceased trading and will no longer be listed on the New York Stock Exchange.

Back to all articles
Newsletter

Where the Money Moved

The intelligence briefing of the innovation economy. Funding, M&A, debt and fund closes, read as market signal rather than deal announcements.

Subscribe to Where the Money Moved
I

Integer Holdings Corporation

Global medical-device contract development and manufacturing organization

  • Plano, Texas
WebsiteLinkedIn

Key Executives

  • Payman Khales
  • President and CEO

Investors

KKR
View Career Page

Related Articles

Funding Announcement
Johnson & Johnson Agrees to $2.2B Ollin Biosciences Buyout
Nov 17, 2026
Funding Announcement
Mubadala and Centerbridge Agree to Buy Canaccord Wealth
Nov 17, 2026
Funding Announcement
Trusted Space Acquires Falcon ExoDynamics for Space Autonomy
Nov 14, 2026
Funding Announcement
eToro Agrees to Acquire LB Finanzas for Latin America
Nov 14, 2026
Funding Announcement
XRHealth Acquires PursueCare for Connected Addiction Care
Nov 14, 2026

More from Jesse Landry

Funding Announcement
Valkryn Raises $15M Seed for Autonomous Defense Testing
Nov 18, 2026
Funding Announcement
Argonaut Private Equity Closes $606M Fund VI for Industrials
Nov 18, 2026
Funding Announcement
Compute Desk Raises $45M Seed for GPU Compute Markets
Nov 18, 2026

Trending

Events
Decoded Futures Brings a Year of Nonprofit AI Work Back Into the Room
Nov 17, 2026
News
Serve Robotics Opens Physical AI Services to Outside Fleets
Nov 15, 2026
View all posts